Clinical Trial

SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

Study acronym: SAFEGUARD
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2b, investigator- and participant-blinded, placebo-controlled, parallel-arm study to evaluate the efficacy, safety and tolerability of SAB 142 in patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D).
Protocol Amendment History 1 change
notable Trial sites expanded: 66 -> 71 locations 2026-05-30
Trial Details
NCT Number NCT07187531
Lead Sponsor SAb Biotherapeutics, Inc.
Conditions Type 1 Diabetes
Enrollment 159 participants
Start Date 2025-11-25
Primary Completion 2027-11 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-10